Erbium:YAG laser pretreatment accelerates the response of Bowen's disease treated by topical 5-fluorouracil

Dermatol Surg. 2004 Mar;30(3):441-5. doi: 10.1111/j.1524-4725.2004.30122.x.

Abstract

Background: Topical 5-fluorouracil (5-FU) is a standard treatment for Bowen's disease. However, its efficacy may be limited by the presence of stratum corneum. The Er:YAG laser has shown a dramatic enhancement effect on the delivery of 5-FU in vitro by ablation of the stratum corneum. The efficacy of laser-assisted delivery of 5-FU has not been tested in human.

Objective: To see whether Er:YAG laser pretreatment can improve the efficacy of topical 5-FU in the treatment of Bowen's disease.

Methods: Three target lesions from a patient with multiple Bowen's disease were selected for a half-side comparison study. The Er:YAG laser was used to remove the cornified layer on one side of each lesion, followed by twice-daily application of 5-FU cream to both sides. Clinical and histologic responses were compared.

Results: Lesions pretreated with the Er:YAG laser showed more rapid clinical and histologic responses to topical 5-FU than those treated with 5-FU alone. Evaluation at 9 months after treatment showed no recurrences of lesions on both sides.

Conclusions: Our preliminary study demonstrates that this Er:YAG laser-assisted modality is effective and shows accelerated clinical response and shortened treatment time compared with topical 5-FU as a single treatment.

Publication types

  • Case Reports

MeSH terms

  • Administration, Topical
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Bowen's Disease / drug therapy*
  • Bowen's Disease / radiotherapy*
  • Combined Modality Therapy
  • Fluorouracil / administration & dosage*
  • Humans
  • Laser Therapy*
  • Male
  • Middle Aged
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / radiotherapy*

Substances

  • Antimetabolites, Antineoplastic
  • Fluorouracil